
|Articles|February 1, 2005
Fixed-combination drug yields superior IOP lowering
New Orleans—Results of a prospective, randomized, double-masked study demonstrate a fixed combination of travoprost 0.004% and timolol 0.5% (Extravan, Alcon Laboratories) administered once daily is safe, well-tolerated, and offers better IOP lowering than monotherapy using either of its components, said Howard S. Barnebey, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Q&A: As DMEI turns 50, R. Michael Siatkowski, MD, MBA, looks to the future
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week
5

















































.png)


